NCI News
Study of “exceptional responders” yields clues to cancer and potential treatments
11/19/2020
A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.
NCI, NIBIB award contracts to develop innovative digital health technologies for COVID-19
9/15/2020
NCI and the National Institute of Biomedical Imaging and Bioengineering have awarded seven contracts to develop digital health solutions, like smartphone apps, wearable devices, and software, that help address the COVID-19 pandemic.
NCI and Cancer Research UK will partner to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research.
New treatments spur sharp reduction in lung cancer mortality rate
8/12/2020
Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, an NCI study shows.
AI dual-stain approach improved accuracy, efficiency of cervical cancer screening in NCI study
6/25/2020
In a new study, an automated dual-stain method using artificial intelligence improved the accuracy and efficiency of cervical cancer screening compared with the current standard for follow-up of women who test positive with primary HPV screening.
NIH scientists develop blood test to help improve liver cancer screening
6/11/2020
The new test is relatively simple and could improve screening for people who are at risk for developing hepatocellular carcinoma (HCC), the most common form of liver cancer. It could help doctors find and treat HCC early.
Study identifies potential approach to treat severe respiratory distress in patients with COVID-19
6/05/2020
As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.
In an NCI study, an alternative treatment regimen called dose-adjusted EPOCH-R that is less toxic than standard dose-intensive chemotherapy was highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.
Higher daily step count linked with lower all-cause mortality
3/24/2020
In a new study, higher daily step counts were associated with lower mortality risk from all causes. Researchers found that the number of steps taken each day, but not the intensity of the stepping, had a strong association with mortality.
NCI statement on clinical trials during COVID-19 pandemic
3/19/2020
Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.